Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation ; volume:11 ; number:1 ; day:13 ; month:1 ; year:2021 ; pages:1-14 ; date:12.2021
Scientific reports ; 11, Heft 1 (13.1.2021), 1-14, 12.2021
- Creator
-
Elabi, Osama
Gaceb, Abderahim
Carlsson, Robert
Padel, Thomas
Soylu-Kucharz, Rana
Cortijo, Irene
Li, Wen
Li, Jia-Yi
Paul, Gesine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-80889-8
- URN
-
urn:nbn:de:101:1-2021020723375905612673
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Elabi, Osama
- Gaceb, Abderahim
- Carlsson, Robert
- Padel, Thomas
- Soylu-Kucharz, Rana
- Cortijo, Irene
- Li, Wen
- Li, Jia-Yi
- Paul, Gesine
- SpringerLink (Online service)
Other Objects (12)
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models